Athersys Inc (ATHXQ PINK) stock market data APIs
$0
0(0%)
as of March 13, 2026
Try our APIs with
free plan!
Athersys Inc Financial Data Overview
Price chart is built with
Anychart
Athersys, Inc., a clinical-stage biotechnology company, develops therapies in the regenerative medicine area. Its stem cell product candidate is the MultiStem cell therapy, an allogeneic stem cell product for the treatment of indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other critical care conditions. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On September 24, 2024, the voluntary petition of Athersys, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy along with its affiliates on January 5, 2024.
Prev. Close
0
Open
0
High
0
Low
0
52 wk Range
0-0.0001
Market Cap
617
Shares Outstanding
61 719 K
Revenue
80 000
EPS
0
Beta
55.447
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Athersys Inc data using free add-ons & libraries
Get Athersys Inc Fundamental Data
Athersys Inc Fundamental data includes:
- Net Revenue: 80 000
- EBITDA: -28 217 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-25
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Athersys Inc News
New
Regenerative Medicine Market Research Report 2025 Featuring Stryker, Athersys, Integra Lifesciences, Isto Biologics, Organogenesis, CryoLife, Medtronic, U.S. Stem Cell, Zimmer Biomet, and 3M
Company Logo The regenerative medicine market offers significant opportunities in personalized stem cell therapies, driven by rising cancer cases and demand for effective chronic disease treatments. ...
![[Latest] Global Cardiac Tissue Engineering Market Size/Share Worth USD 2,943.92 Million by 2034 at a 16.65% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)](/build/assets/fallback2-B-N5xr-q.jpg)
[Latest] Global Cardiac Tissue Engineering Market Size/Share Worth USD 2,943.92 Million by 2034 at a 16.65% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cardiac Tissue Engineering Market size & shar...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
